Telomir Pharma reports peer-reviewed Telomir-Zn data showing survival benefit in Wilson's disease model

Telomir Pharmaceuticals, Inc.

Telomir-Zn dose-dependently improved survival, reduced hepatic copper burden and liver injury biomarkers (ALT, AST, bilirubin) in zebrafish Wilson's disease model.
Preclinical study published in Advances in Redox Research; demonstrates reductions in oxidative stress, ROS-Ca²⁺ amplification, and tissue degeneration.
First peer-reviewed publication for Telomir-Zn in Wilson's disease; supports mechanism across copper-redox modulation and mitochondrial protection.
Telomir-Zn already has FDA IND clearance for Phase 1/2 in Triple-Negative Breast Cancer (April 2026); new data further validates platform.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.